HA-DOTATATE - Radioligand, precursor for radiolabeled HA-DOTATATE and ligand for somatostatin receptors. Can be bound to radionuclides for development of cancer treatment and diagnosis. For research use only!
HA-DOTATATE - Radioligand - Specifications
- Peptide sequence: DOTA-DPhe-C-Tyr(3-I)-DTrp-KTCT-OH (Tyr(3-I) = 3-iodo-L-tyrosine
- Amount: 2 mg (20 x100µg)
- Purity: >95% (HPLC-MS)
- Delivery Format: Freeze-dried in plastic vial
- Application(s): Nuclear medicine
- Condition(s)/Topic(s): Cancer
- Standard Delivery Time: approx. 3 weeks
Are you interested in other peptides or conjugation to a protein, nucleic acid or lipid? Choose your sequence, amount and purity with our
Custom Peptide Synthesis services.
We provide the peptide in a range of aliquot sizes, ensuring flexibility for diverse research applications. For any special requirements, please contact our customer support: peptide@jpt.com
JPT’s Oncology Peptides
One focus of JPT’s product development is oncology. Therefore, we offer a huge variety of TAA peptide, peptide pools and microarrays, as well as DOTA peptides and radio sensitizers. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides in all formats, scales and modifications to the global scientific community. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.Have a look at our Peptide Tools to Study Cancer.
Benefits of JPT's Single Catalogue Peptides
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
-CAS909024-55-1.jpg "DOTA-cyclo(RGDfK) - CAS 909024-55-1")
